武田制药 TAK 深 沪
等待开盘 04-01 09:30:00 美东时间
18.52
+0.250
+1.37%
华盛通- 最 高18.59
- 今 开18.22
- 成交量 494.52万股
- 最 低 18.18
- 昨 收 18.27
- 总市值 585.08亿
- 52周最高 18.82
- 市盈率 静 83.99
- 换手率 0.16%
- 52周最低 12.99
- 委 比 -21.32%
- 总股本 31.59亿
- 历史最高 18.82
- 量 比 1.79
- 振 幅 2.24%
- 历史最低 8.7904
- 每 手 1
- 风险率 1.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Takeda Canada Presents New Data From Two Pivotal Phase 3 Trials Of Zasocitinib To Treat Severe Plaque Psoriasis; About 70% Of Patients Treated With Zasocitinib Achieved Clear Or Almost Clear Skin At Week 16
Takeda Canada Inc. ("Takeda") is pleased to announce new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults
03-31 20:19
【里程碑】4周起效、60周持续应答！武田公布银屑病口服药Zasocitinib 3期新数据
（来源：动脉新医药） 在3期斑块状银屑病研究中，约70%接受Zasocitinib治疗的患者在第16周达到皮损清除或几乎清除（sPGA 0/1） ...
03-30 12:01
Takeda revamps business seeking ¥200B in savings by FY28
Takeda (TAK) announced plans to generate more than ¥200B ($1.3B) in annualized gross savings by fiscal 2028 on Wednesday, citing a business transformation exercise and a recently undertaken restructur...
03-25 22:27
武田制药(TAK.US)拟计提1500亿日元重组费用，以AI驱动降本增效
日本制药巨头武田制药计划在即将于下月开启的新财年中计提约1500亿日元(约合9.45亿美元)的重组费用。
03-25 19:31
'Takeda, Lilly Rejected by Supreme Court on Actos Fraud Lawsuit' - Bloomberg
https://www.bloomberg.com/news/articles/2026-03-23/takeda-lilly-rejected-by-supreme-court-on-actos-fraud-lawsuit
03-23 22:12
Takeda And Protagonist Say FDA Grants Priority Review For Rusfertide As Potential First-In-Class Therapy For Polycythemia Vera, Backed By Phase 3 VERIFY Data
Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily Based on Phase 3
03-02 16:20
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value Catalysts Market News Updates News Commentary NEW YORK, Feb. 24, 2026 /PRNewswire/...
02-24 22:35
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
FDA grants Breakthrough Therapy status to Rybrevant for advanced cancer while Trellus Health extends IBD support contract.
02-18 23:10
美股盘前 | Sandisk Corporation涨6.60%，武田制药涨5.85%
Sandisk Corporation涨6.60%；武田制药涨5.85%；美光科技涨3.56%
02-12 17:22
